23rd Conference on Retroviruses and Opportunistic Infections (CROI 2016), 22-25 February 2016, Boston
Every year, CROI brings more than 5000 researchers, doctors, community activists and other health workers to meet for one of the most scientifically important HIV conferences.
This year the meeting was in Boston and with over 1000 studies presented, there is far more to report than the key studies that make headline news.
At CROI 2016, major studies presented research on basic and clinical science relating to prevention, new treatment and global access.
The programme and abstracts are posted to the conference website, with many posters also available as PDF files.
Webcasts from all oral presentations are also online.
Reports in this issue of HTB are:
- Dual long-acting injections of cabotegravir plus rilpivirine: 32-week results from LATTE-2 study
- New NRTI MK-8591: weekly oral dosing and once-yearly slow-release dosing has potential for HIV treatment and PrEP
- Similar viral load reductions at week 4 when dolutegravir is used with 2- or 3-drug initial ART
- 48-week results for NNRTI doravirine compared to efavirenz
- Dramatic increase in use of oral TDF/FTC for PrEP in the US – plus a few cautions
- Future oral and long-acting PrEP: pills, films, gels, injections and depots
- First data on TAF as PrEP to prevent HIV infection
- Longacting cabotegravir as PrEP protects macaques against IV exposure but will need two-monthly injections in human studies
- Role for maraviroc as HIV PrEP likely need dual combinations
- Dapivirine vaginal ring shows only limited PrEP protection against HIV for African women
- Early data from dolutegravir use during pregnancy
- Dolutegravir: 48 week results in children aged 6 to 12 years
- New antiretrovirals could mean savings up to US $3 billion by 2025
- Countries with lower HIV prevalence have lower ART coverage
- Nigerian herbal medicines widely used by HIV positive people can contain antiretrovirals
- Cure research news from CROI 2016